Skip to main content

Peer Review reports

From: The increase in activating EGFR mutation in plasma is an early biomarker to monitor response to osimertinib: a case report

Original Submission
5 Apr 2018 Submitted Original manuscript
19 Oct 2018 Author responded Author comments - Eleonora Rofi
26 Jul 2018 Reviewed Reviewer Report - Kadoaki Ohashi
24 Sep 2018 Reviewed Reviewer Report - Reviewer 2
Resubmission - Version 2
19 Oct 2018 Submitted Manuscript version 2
6 Mar 2019 Author responded Author comments - Marzia Del Re
6 Nov 2018 Reviewed Reviewer Report - Kadoaki Ohashi
Resubmission - Version 3
6 Mar 2019 Submitted Manuscript version 3
9 Apr 2019 Author responded Author comments - Marzia Del Re
Resubmission - Version 4
9 Apr 2019 Submitted Manuscript version 4
Publishing
12 Apr 2019 Editorially accepted
30 Apr 2019 Article published 10.1186/s12885-019-5604-6

You can find further information about peer review here.

Back to article page
\